1 Spectacular Growth Stock Down 20% to Buy Right Now, According to Wall Street

Now, it’s worth noting Stock Advisor's total average return is 1,064% — a market-crushing outperformance compared to 194% for ...
Medical Device and Diagnostic Industry (MD+DI)

Dexcom Faces G6 Recall

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose ...

DexCom (DXCM): Assessing Valuation After Surge in Lawsuits Over Device Safety and Reliability

DexCom (DXCM) is under the spotlight after several class action lawsuits were filed claiming the company made unauthorized changes to its G6 and G7 glucose monitoring devices. These changes could ...
Fierce Biotech

Dexcom hit by FDA Class I recall for its continuous glucose monitoring system app

Dexcom has been hit by a major safety issue for an Android version of its G6 continuous monitoring system app, leading the FDA to issue its most serious recall notice. | Dexcom has been hit by a major ...

Legal and Regulatory Scrutiny Over Device Changes Might Change the Case for Investing in DexCom (DXCM)

Recently, multiple class action lawsuits were filed against DexCom, Inc. after reports surfaced alleging the company made unauthorized design changes to its G6 and G7 continuous glucose monitoring ...